<DOC>
	<DOCNO>NCT00001082</DOCNO>
	<brief_summary>To evaluate safety efficacy adefovir dipivoxil prolong survival patient advance HIV disease . In CMV prophylaxis substudy : To evaluate efficacy adefovir dipivoxil prevent development CMV end-organ disease patient advance HIV coinfected CMV . The optimal treatment HIV infection prevention CMV disease identify . Currently available antiretroviral therapy hamper significant toxicity development resistance . In addition , agent prevent CMV disease , oral ganciclovir , complicate poor bioavailability decrease compliance secondary toxicity . Moreover , discordant result report regard effectiveness oral ganciclovir prevent CMV disease . There need new agent anti-HIV anti-herpesvirus activity good pharmacokinetic safety profile well tolerated patient . Adefovir dipivoxil oral pro-drug PMEA , nucleoside analog activity broad spectrum retrovirus herpesviruses , include important human pathogen , HIV-1 , HIV-2 CMV . Due anti-HIV anti-herpesvirus activity , adefovir dipivoxil may able decrease incidence opportunistic herpesvirus infection prolong survival patient advance HIV infection .</brief_summary>
	<brief_title>The Safety Effectiveness Adefovir Dipivoxil Treatment HIV-Infected Patients</brief_title>
	<detailed_description>The optimal treatment HIV infection prevention CMV disease identify . Currently available antiretroviral therapy hamper significant toxicity development resistance . In addition , agent prevent CMV disease , oral ganciclovir , complicate poor bioavailability decrease compliance secondary toxicity . Moreover , discordant result report regard effectiveness oral ganciclovir prevent CMV disease . There need new agent anti-HIV anti-herpesvirus activity good pharmacokinetic safety profile well tolerated patient . Adefovir dipivoxil oral pro-drug PMEA , nucleoside analog activity broad spectrum retrovirus herpesviruses , include important human pathogen , HIV-1 , HIV-2 CMV . Due anti-HIV anti-herpesvirus activity , adefovir dipivoxil may able decrease incidence opportunistic herpesvirus infection prolong survival patient advance HIV infection . All patient enrol within first 18 month study . They randomize 1 2 group . Group 1 comprise 1080 patient receive adefovir dipivoxil plus L-carnitine group 2 comprised 1080 patient receive placebo plus L-carnitine . At least first 400 patient enrol ( 200 group ) comprise safety-HIV virology cohort . These patient frequent follow visit , additional laboratory evaluation , intensive safety data information first 6 month . NOTE : At least 850 patient infected CMV follow development CMV end-organ disease CMV prophylaxis substudy . AS PER AMENDMENT 8/7/97 : All patient enrol primary study randomize treatment placebo regimen . Within primary study , patient meet specified criterion may enrol one follow cohort : 1 . Safety-HIV virology cohort ( least first 400 patient enrol study regardless CMV status ) . 2 . CMV bDNA cohort ( patient safety-HIV virology cohort CMV-positive ) . 3 . CMV-virology cohort ( first 400 patient CMV bDNA cohort enrol site able obtain CMV urine culture ) . All patient CMV-positive enrolled CMV prophylaxis substudy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chronically administer concomitant therapy HIV opportunistic disease , include chemotherapy cutaneous Kaposi 's sarcoma , must therapies least 30 day prior study entry . Short course oral antibiotic therapy give limited period 3 week . Episodic use IV acyclovir oral acyclovir &gt; 1g/day treatment acute illness permit clinician 's discretion . Patients must : A work diagnosis HIV infection base patient 's medical history , behavioral history , clinical sign symptom , result laboratory test . CD4+ cell count &lt; = 100 cells/mm3 within 60 day prior randomization ( OR , AS PER AMENDMENT 8/7/97 , CD4+ cell count &gt; 100 &lt; = 200 cells/mm3 within 60 day prior randomization document nadir CD4+ cell count &lt; = 50 cells/ mm3 time prior randomization ) . Reasonably good health . Life expectancy least 6 month . Access refrigerator storage adefovir dipivoxil . Signed informed consent parent legal guardian patient le 18 year age . AS PER AMENDMENT 8/7/97 : CMV serology ( IgG ) positive ( CMV bDNA cohort CMVvirology cohort ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Evidence active CMV disease screen . Conditions would require use medication list Exclusion Concurrent Medications . Concurrent Medication : Excluded : Any investigational antiCMV agent . Adenine arabinoside ( vidarabine ) . Amantadine hydrochloride ( Symmetrel ) . Cidofovir ( Vistide ) . CMV hyperimmune globulin . Cytosine arabinoside ( cytarabine ) . Famciclovir . Foscarnet ( phosphonoformic acid ) . Ganciclovir ( Cytovene ) . GW 1263W94 ( Benzamidazole ) . Idoxuridine . Intravenous acyclovir . ISIS 2922 ( Antisense ) . Lobucavir . MSL109 . Oral acyclovir &gt; 1 g/day . Valacyclovir . Patients follow prior condition exclude : History CMV endorgan disease . Prior Medication : Excluded within 2 week randomization : Any investigational antiCMV agent . Adenine arabinoside ( vidarabine ) . Amantadine hydrochloride ( Symmetrel ) . Cidofovir ( Vistide ) . CMV hyperimmune globulin . Cytosine arabinoside ( cytarabine ) . Famciclovir . Ganciclovir ( Cytovene ) . GW 1263W94 ( Benzamidazole ) . Idoxuridine . Intravenous acyclovir . ISIS 2922 ( Antisense ) . Lobucavir . MSL109 . Oral acyclovir &gt; 1 g/day . Valacyclovir . Excluded within 60 day prior study entry : Foscarnet .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Prodrugs</keyword>
	<keyword>Survival</keyword>
	<keyword>Adenine</keyword>
</DOC>